Simran DS Maggo

Dr. Simran DS Maggo

Pharmacy, Shenandoah University, Winchester, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
PKPing Siu Kee
Ping Siu Kee
PCPaul Ken Leong Chin
Paul Ken Leong Chin
MKMartin A. Kennedy
Martin A. Kennedy
Simran DS MaggoSimran DS Maggo
Simran DS Maggo
Statins, a class of lipid-lowering medications, have been a keystone treatment in cardiovascular health. However, adverse effects associated with statin use impact patient adherence, leading to statin discontinuation. Statin-induced myotoxicity (SIM) is one of the most common adverse effects, prevalent across all ages, genders, and ethnicities. Although certain demographic cohorts carry a higher risk, the impaired quality of life attributed to SIM is significant. The pathogenesis of SIM remains to be fully elucidated, but it is clear that SIM is multifactorial. These factors include drug–drug interactions, renal or liver dysfunction, and genetics. Genetic-inferred risk for SIM was first reported by a landmark genome-wide association study, which reported a higher risk of SIM with a polymorphism in the SLCO1B1 gene. Since then, research associating genetic factors with SIM has expanded widely and has become one of the foci in the field of pharmacogenomics. This review provides an update on the genetic risk factors associated with SIM.

1 January 2011 in Drug Safety
Verified
Journal Article
Closed access
PDF file
Simran DS MaggoSimran DS Maggo
Simran DS Maggo
MKMartin Alexander Kennedy
Martin Alexander Kennedy
DCDavid W. J. Clark
David W. J. Clark

27 September 2019 in Pharmacogenomics
Verified
Journal Article
Closed access
YLYusmiati Liau
Yusmiati Liau
Simran DS MaggoSimran DS Maggo
Simran DS Maggo
AMAllison L Miller
Allison L Miller
JPJohn F Pearson
John F Pearson
MKMartin Alexander Kennedy
Martin Alexander Kennedy
SCSimone L Cree
Simone L Cree
Aim: Long read sequencing offers the promise of overcoming some of the challenges in accurate genotyping of complex genes, along with the advantage of straightforward variant phasing. We have estab...

8 December 2018 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
YLYusmiati Liau
Yusmiati Liau
ICIgnatius Chua
Ignatius Chua
MKMartin A. Kennedy
Martin A. Kennedy
Simran DS MaggoSimran DS Maggo
Simran DS Maggo

1 January 2012 in Drug Safety
Verified
Journal Article
Closed access
PDF file
MHMira Harrison-Woolrych
Mira Harrison-Woolrych
Simran DS MaggoSimran DS Maggo
Simran DS Maggo
MTMing Tan
Ming Tan
RSRuth Savage
Ruth Savage
JAJanelle Ashton
Janelle Ashton

15 February 2012 in NeuroReport
Verified
Journal Article
Closed access
JRJack R. Rivers
Jack R. Rivers
Simran DS MaggoSimran DS Maggo
Simran DS Maggo
JAJohn C. Ashton
John C. Ashton
Neonatal cerebral ischemic injury is a common and debilitating pathology for which there is currently no known purely pharmacological treatments that are effective when delivered immediately after injury. Cyclodextrins are cyclic oligosaccharides that can remove cholesterol from cell membranes and thereby affect receptor function. Cyclodextrins have previously been shown to be neuroprotective in vitro. We showed that hydroxypropyl-β-cyclodextrin is neuroprotective in rats in vivo when delivered by intraperitoneal injection 30 min following hypoxia-ischemia, when assessed 15 days after surgery. A single dose of 1 g/kg hydroxypropyl-β-cyclodextrin reduced brain infarction size by 28.57% compared with control (P<0.001). We also report that the same compound reduces neuronal excitability in hippocampal slices and propose that hydroxypropyl-β-cyclodextrin is neuroprotective by reducing excitotoxicity in the delayed phase of brain damage.